US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...

Louisville is a shining example of how to connect disability, civil rights and equity. Combined activism can establish DEI ...

Although fast food can be a tasty treat, many of your favorite menu items contain some very questionable preservatives, dyes, ...

Introduction Globally, tuberculosis (TB) remains one of the leading infectious causes of death, with 1.3 million deaths.

TCTMD spoke with Batchelor about how executive orders on DEI and federal funding are impacting the research ecosystem.

Repeats Raise Risk. The more STR expansions a person carried, the higher their odds for AD (left). People with more repeat expansions tended to have worse tau pathology as per Braak stage (right).